Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

GR, Oxnard; KS, Thress; RS, Alden; R, Lawrance; CP, Paweletz; M, Cantarini; JC, Yang; JC, Barrett; PA, Jänne

doi:10.1200/jco.2016.66.7162

Public

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Shared by NobleBlocks on Jun 27, 2016 • 12:00 AM UTC

Authors:

Oxnard GR

Thress KS

Alden RS

Abstract

Purpose Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction of outcom...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!